DSpace Repository

Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis

Show simple item record

dc.contributor.author Chambergo-Michilot, Diego
dc.contributor.author Runzer-Colmenares, Fernando M.
dc.contributor.author Segura Saldaña, Pedro Antonio
dc.date.accessioned 2023-09-06T20:45:09Z
dc.date.available 2023-09-06T20:45:09Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14073
dc.description.abstract Introduction: COVID-19 related mortality is about 2%, and it increases with comorbidities, like hypertension. Regarding management, there is debatable evidence about the benefits of continuation vs. discontinuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB). Aim: We performed a systematic review to assess the effects and safety of in-hospital discontinuation compared to continuation of ACEI/ARB in COVID-19 patients. Methods: We systematically searched on PubMed, Scopus, and EMBASE from inception to June 19, 2021. We included observational studies and trials that compared the effects and safety of continuing ACEI/ARB compared to discontinuing it in COVID-19 patients. Effects sizes for dichotomous variables were expressed as risk ratios (RR) and 95% confidence intervals. For continuous variables, effects were expressed as mean difference (MD). We used random effect models with the inverse variance method. We assessed certainty of evidence using the GRADE approach. Results: We included three open-label randomized controlled trials and five cohort studies. We found that the continuation group had lower risk of death compared with the discontinuation group only in the cohort group (RR: 0.46, 95% CI: 0.24–0.90), but not in the RCT group (RR: 1.22, 95% CI: 0.75–2.00). The ICU admission rate was significantly lower in the continuation group (RR: 0.46, 95% CI: 0.31–0.68) in the cohort group, but not in RCT group (RR: 1.03, 95% CI: 0.67–1.59). We did not find significant differences between groups regarding hospitalization length, hypotension, AKI needing renal replacement therapy, mechanical ventilation, new or worsening heart failure, myocarditis, renal replacement therapy, arrhythmias, thromboembolic events and SOFA AUC. The GRADE approach revealed that the certainty ranged from moderate to high level. Conclusions: There is no significant difference in mortality and other outcomes between continuation and discontinuation groups. en_US
dc.language.iso eng
dc.publisher Adis
dc.relation.ispartofseries High Blood Pressure and Cardiovascular Prevention
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject COVID-19 en_US
dc.subject Hypertension en_US
dc.subject Angiotensin-converting enzyme inhibitors en_US
dc.subject Angiotensin receptor antagonists en_US
dc.subject Systematic review en_US
dc.subject.mesh COVID-19
dc.subject.mesh Hipertensión
dc.subject.mesh Inhibidores de la Enzima Convertidora de Angiotensina
dc.subject.mesh Antagonistas de Receptores de Angiotensina
dc.subject.mesh Revisión Sistemática
dc.title Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1007/s40292-023-00579-0
dc.relation.issn 1179-1985


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics